Pre-Header Contact

800-449-3353 | |

Footer Socials

Pre-Header Menu

Careers | Contact Us

Investor Relations

Press Release Details

Rockwell Medical Reports Fourth Quarter and Year End 2017 Results

March 15, 2018 at 4:01 PM EDT

Conference call at 4:30 p.m. EDT today

WIXOM, Mich., March 15, 2018 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (NASDAQ:RMTI), a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with innovative products and services for the treatment of iron replacement, secondary hyperparathyroidism and hemodialysis, reported results for the fourth quarter and year ending December 31, 2017.

Q4 2017 Financial Highlights

  • Sales were $14.8 million, $1.4 million or 10.8% higher than Q4 2016
  • The company reported a negative gross profit of ($1.2) million compared to $2.0 million gross profit in Q4 2016 due to a $3.3 million reserve incurred for expiring pharmaceutical inventory.
  • SG&A expense was $5.9 million compared to $6.0 million in Q4 2016.
  • R&D expense was $2.1 million compared to $1.2 million in Q4 2016.
  • Net loss was ($9.0) million or ($0.18) per share compared to a ($5.1) million net loss or ($0.10) per share in Q4 2016.
  • Cash and investments were $33.1 million as of December 31, 2017.
  • Net working capital was $39.7 million as of December 31, 2017.

2017 Financial Highlights                                                                                                                                                                      

  • Sales were $57.3 million compared to $53.3 million in 2016, with the increase primarily due to higher concentrate unit volume.
  • Gross profit was $3.7 million compared to $6.8 million in 2016. Gross profit was adversely impacted by increased drug product costs of $1.9 million and lower gross profit of $1.0 million on our concentrate business.
  • SG&A expense was $23.3 million compared to $21.1 million in 2016.
  • R&D expense was $6.3 million compared to $5.8 million in 2016.
  • Net loss was ($25.9) million or ($0.51) per share versus ($19.8) million or ($0.39) per share in 2016.
  • Cash used in operating activities in 2016 was $21.1 million.

2017 Corporate Highlights

  • Continued marketing and education of Triferic and in-center use to US dialysis providers.
  • Data from clinics using Triferic via the drug sample program have shown improved patient outcomes and reduced costs.
  • Proposal submitted to Centers for Medicare and Medicaid Innovation (CMS) for separate reimbursement for Triferic which is under review by CMS.
  • Triferic ESA sparing patent covering composition and use issued in China.
  • Signed exclusive license agreements for Triferic commercialization in Chile and Peru.

Mr. Robert L. Chioini, Chief Executive Officer of Rockwell stated, “We are pleased and excited with the substantial progress we have made working with policy makers in Washington D.C. to ensure hemodialysis patients across the U.S. will have access to our new, innovative anemia therapy Triferic. There is a timely emphasis on spurring innovation in the U.S. renal market to provide new therapies, like Triferic, that can improve patients’ lives and lower healthcare costs. Based on our progress to date, we remain optimistic that Triferic will receive the proper reimbursement soon. Our marketing and education efforts for Triferic continue, and have been well received by the dialysis community. Data reported via our drug sample program has shown positive patient outcomes and cost-saving benefits, giving us further confidence that Triferic should be widely adopted if separate reimbursement is granted.”

Conference Call Information
Rockwell Medical will be hosting a conference call to review its 2017 fourth quarter and year end results today, Thursday, March 15, 2018 at 4:30 p.m. EDT.  Investors are encouraged to call a few minutes in advance at (866) 548-4713, or for international callers (323) 794-2093, Conference ID #8976030. To listen to the call via webcast, please go to the Rockwell Medical IR web page:

About Triferic
Triferic is the only FDA approved drug indicated to replace iron and maintain hemoglobin in hemodialysis patients suffering from anemia. Via dialysate during each dialysis treatment, Triferic replaces the 5-7 mg iron loss that occurs in all patients, effectively maintaining their iron balance. Unlike IV iron products, Triferic binds iron immediately and completely to transferrin (carrier of iron in the body) upon entering the blood and it is then transported directly to the bone marrow to be incorporated into hemoglobin, with no increase in ferritin (stored iron and inflammation) and no anaphylaxis, addressing a significant unmet need in overcoming Functional Iron Deficiency (FID) in ESRD patients. Please visit to view the Triferic mode-of-action (MOA) video and for more information.

About Rockwell Medical, Inc.
Rockwell Medical, Inc. (“Rockwell”) is a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with innovative products and services for the treatment of iron replacement, secondary hyperparathyroidism and hemodialysis.

Rockwell’s FDA approved drug Triferic is indicated for iron replacement and maintenance of hemoglobin in hemodialysis patients suffering from anemia. Triferic delivers iron to patients during their regular dialysis treatment, using dialysate as the delivery mechanism. Triferic has demonstrated that it safely and effectively delivers sufficient iron to the bone marrow and maintains hemoglobin, without increasing iron stores (ferritin). Rockwell intends to market Triferic to hemodialysis patients in the U.S. dialysis market and globally.

Rockwell’s FDA approved generic drug Calcitriol is for treating secondary hyperparathyroidism in dialysis patients. Calcitriol (active vitamin D) injection is indicated in the management of hypocalcemia in patients undergoing chronic renal dialysis. It has been shown to significantly reduce elevated parathyroid hormone levels. Reduction of PTH has been shown to result in an improvement in renal osteodystrophy.  Rockwell intends to market Calcitriol to hemodialysis patients in the U.S. dialysis market.

Rockwell is also an established manufacturer and leader in delivering high-quality hemodialysis concentrates/dialysates to dialysis providers and distributors in the U.S. and abroad. As one of the two major suppliers in the U.S., Rockwell’s products are used to maintain human life by removing toxins and replacing critical nutrients in the dialysis patient’s bloodstream. Rockwell has three U.S. manufacturing/distribution facilities.

Rockwell’s exclusive renal drug therapies support disease management initiatives to improve the quality of life and care of dialysis patients and are intended to deliver safe and effective therapy, while decreasing drug administration costs and improving patient convenience. Rockwell Medical is developing a pipeline of drug therapies, including extensions of Triferic for indications outside of hemodialysis. Please visit for more information.

Forward-Looking Statement Disclaimer
Certain statements in this press release constitute "forward-looking statements" within the meaning of the federal securities laws, including, but not limited to, Rockwell’s prospects of obtaining the approval from CMS for separate reimbursement for Triferic and its intention to sell and market Calcitriol and Triferic. Words such as “may,” “might,” “will,” “should,” “believe,” “expect,” “anticipate,” “estimate,” “continue,” “could,” “potential,” “predict,” “forecast,” “project,” “plan,” “intend” or similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. While Rockwell believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to us on the date of this release.  These forward looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties, including without limitation those set forth in Rockwell Medical’s SEC filings many of which are beyond our control, actual results could be materially different.  Rockwell expressly disclaims any obligation to update or alter statements whether as a result of new information, future events or otherwise, except as required by law.

Triferic® is a registered trademark of Rockwell Medical, Inc.

Investor Contact:
Michael Rice
LifeSci Advisors
(646) 597-6979 

Media Contact:
Matt Middleman
LifeSci Public Relations
(646) 627-8384 

Source: Rockwell Medical, Inc.

For the three and twelve months ended December 31, 2017 and December 31, 2016
    Three Months Ended
December 31, 2017
    Three Months Ended
December 31, 2016
Year Ended
December 31, 2017
  Year Ended
December 31, 2016 
Sales $  14,838,016     $  13,389,786   $  57,300,281     $  53,284,166  
Cost of Sales    16,062,936        11,401,603      53,598,390        46,531,648  
Gross Profit (Loss)    (1,224,920 )      1,988,183      3,701,891        6,752,518  
Selling, General and Administrative    5,869,879        6,049,663      23,303,409        21,120,901  
Research and Product Development    2,126,397        1,200,729      6,321,400        5,840,346  
Operating (Loss)   (9,221,196 )     (5,262,209 )   (25,922,918 )     (20,208,729 )
Interest and Investment Income    181,171        207,911      892        810,340  
Foreign Currency Gain (Loss)   742            742        —  
Income (Loss) Before Income Taxes   (9,039,283 )     (5,054,298 )   (25,921,284 )     (19,398,389 )
Income Tax Expense              —        (404,527 )
Net (Loss) $ (9,039,283   $ (5,054,298 ) $  (25,921,284 )   $  (19,802,916 )
  Basic Earnings (Loss) per Share $ (0.18 )   $ (0.10 ) $  (0.51 )   $  (0.39 )
  Diluted Earnings (Loss) per Share $ (0.18 )   $ (0.10 ) $  (0.51 )   $  (0.39 )

As of December 31, 2017 and 2016
    December 31,    December 31,   
    2017   2016
Cash and Cash Equivalents   $  8,406,917     $  17,180,594    
Investments Available for Sale      24,648,459        40,759,703    
Accounts Receivable, net of a reserve of $11,000 in 2017 and $5,000 in 2016      6,355,566        6,393,228    
Inventory      7,637,384        12,141,072    
Other Current Assets      1,779,992        2,034,598    
Total Current Assets      48,828,318        78,509,195    
Property and Equipment, net      2,548,978        1,391,575    
Inventory, Non-Current      5,986,752        1,826,554    
Intangible Assets      4,028        4,382    
Goodwill      920,745        920,745    
Other Non-current Assets      490,819        501,187    
Total Assets   $  58,779,640     $  83,153,638    
Accounts Payable   $  4,222,159     $  5,858,234    
Accrued Liabilities      4,715,712        4,210,151    
Customer Deposits      205,303        77,217    
Total Current Liabilities      9,143,174        10,145,602    
Deferred License Revenue      16,723,318        20,051,737    
Shareholders’ Equity:              
Common Shares, no par value, 51,768,424 and 51,527,711 shares issued and outstanding      273,210,907        268,199,939    
Accumulated Deficit      (240,262,376 )      (214,341,092 )  
Accumulated Other Comprehensive Income      (35,383 )      (902,548 )  
Total Shareholders’ Equity      32,913,148        52,956,299    
Total Liabilities And Shareholders’ Equity   $  58,779,640     $  83,153,638    

For the years ended December 31, 2017 and 2016
    2017   2016    
Cash Flows From Operating Activities:                
Net (Loss)   $  (25,921,284 )   $  (19,802,916 )    
Adjustments To Reconcile Net Loss To Net Cash Used In Operating
Depreciation and Amortization      514,362        762,368      
Share Based Compensation—Non-employee      228,847        —      
Share Based Compensation—Employees      6,945,749        10,346,284      
Loss on Disposal of Assets      10,777        8,168      
Loss on Sale of Investments Available for Sale      792,207        26,820      
Changes in Assets and Liabilities:                
(Increase) in Accounts Receivable      (962,338 )      (1,162,469 )    
(Increase) in Inventory      343,490        (6,095,846 )    
(Increase) in Other Assets      264,975        (1,230,084 )    
(Decrease) Increase in Accounts Payable      (1,636,840 )      1,863,018      
(Decrease) Increase in Other Liabilities      634,238        191,134      
(Decrease) in Deferred License Revenue      (2,099,028 )      (2,065,785 )    
(Decrease) Increase in Deferred Drug License Revenue      (229,390 )      4,706,670      
Changes in Assets and Liabilities      (3,684,893 )      (3,793,362 )    
Cash (Used In) Operating Activities      (21,114,235 )      (12,452,638 )    
Cash Flows From Investing Activities:                
Purchase of Investments Available for Sale      (35,733,677 )      (25,781,853 )    
Sale of Investments Available for Sale      51,918,745        24,491,677      
Purchase of Equipment      (1,682,913 )      (355,264 )    
Proceeds on Sale of Assets      725        1,000      
Cash Provided by (Used In) Investing Activities      14,502,880        (1,644,440 )    
Cash Flows From Financing Activities:                
Proceeds from Issuance of Common Shares      123,603        80,161      
Restricted Stock Retained in Satisfaction of Tax Liabilities      (2,287,231 )      —      
Cash (Used In) Provided By Financing Activities      (2,163,628 )      80,161      
Effects of exchange rate changes      1,306        (671 )    
(Decrease) In Cash      (8,773,677 )      (14,017,588 )    
Cash At Beginning Of Period      17,180,594        31,198,182      
Cash At End Of Period   $  8,406,917     $  17,180,594      


Primary Logo

Source: Rockwell Medical, Inc.

Shareholder Tools

Email Alerts
RSS News Feeds